靶向肿瘤微环境的CAR-T治疗研究

CAR-T Therapy Targeting Tumor Microenvironment

癌症仍然是现阶段威胁人类健康的一大难题,随着医学的发展,癌症治疗方法除传统方法:手术、放疗、化疗,还可以采用免疫疗法。目前,癌症免疫疗法受到广泛关注,但在应用方面具有许多局限性,如PD-1/PD-L1抑制剂,在应用的过程中会出现获得性耐药现象,因此细胞免疫疗法(chimeric antigen receptor T cell,CAR-T)应运而生,成为弥补免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)和单克隆抗体药物缺陷的新兴治疗方式,简要介绍了CAR-T免疫疗法的产生、应用及对TME相关靶点的研究进展,为后续研究提供一定的思路。

Cancer is still a major problem threatening human health in recent years.With the development of medicine, besides the traditional methods of cancer treatment: surgery, radiotherapy, chemotherapy,immunotherapy can also be used.At present,cancer immunotherapy has been widely concerned,but there are many limitations in its application.For example,PD-1/PD-L1 inhibitors are found to have acquired drug resistance in the process of application.Therefore,cellular immunotherapy( chimeric antigen receptor T cell,CAR-T) emerges as the times require,becoming a new treatment method to make up for the defects of immune checkpoint inhibitors( ICIs) and monoclonal antibody drugs.Through briefly introduces the emergence and application of CAR-T immunity therapy and the research progress on TME related targets,providing certain ideas for the follow-up research.